APP and Alzheimer disease: Specifically, pharmacologically relevant studies have demonstrated at the cellular and molecular levels that tianma could prevent AD by modulating proteolytic processing of amyloid beta precursor protein (APP), driving the nonamyloidogenic pathway (Figure 2) [41–44, 46].